Phase III studies of investigational Trilipix™ (SLV348/ABT-335), in combination with statins, meets primary endpoints on improving LDL, triglycerides and HDL

TriLipix™ in combination with statins improved all three key lipids and had reported safety consistent with TriLipix™ or statin monotherapies